Search Results

You are looking at 81 - 90 of 116 items for :

  • "novel therapy" x
  • All content x
Clear All
Full access

Gauri R. Varadhachary

several CUP profiles. Physicians who treat CUP are excited about the emerging significance of molecular profiling, and continued experience with commercial ToO assays helps them recognize when and where these tests will be most helpful. As novel therapies

Full access

Terrell Johnson, Lindsey A.M. Bandini, Darryl Mitteldorf, Elizabeth Franklin, Justin E. Bekelman, and Robert W. Carlson

cancer therapy space. 17 The rapid expansion of novel therapies, resulting in more treatment options than ever before, is prompting stakeholders to request more patient experience data from investigators and pharmaceutical companies to help patients and

Full access

Michelle Guan, Gillian Gresham, Arvind Shinde, Isaac Lapite, Jun Gong, Veronica R. Placencio-Hickok, Christopher B. Forrest, and Andrew E. Hendifar

previously validated domains from the PROMIS initiative, we contrasted these patients’ reports with those of other clinical populations and hoped to increase the consistency and efficiency of PRO use in both clinical care and novel therapy development for

Full access

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Asher Chanan-Khan, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Cristina Gasparetto, Carol Ann Huff, Madan Jagasia, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Guido Tricot, Julie M. Vose, Donna Weber, Joachim Yahalom, and Furhan Yunus

novel therapies . Blood 2008 ; 111 : 2516 – 2520 . 4 Hideshima T Anderson KC . Molecular mechanisms of novel therapeutic approaches for multiple myeloma . Nat Rev Cancer 2002 ; 2 : 927 – 937 . 5 Kyle RA Gertz MA Witzig TE

Full access

Reece J. Knippel and Cynthia L. Sears

composition of the microbiome of patients with EO-CRC are warranted to determine whether a distinct microbial signature can be identified. Furthermore, as we learn more about specific bacteria as CRC instigators, screens for prevention and novel therapies may

Full access

Luciano J. Costa and Saad Z. Usmani

performed in the pre–novel therapy era and therefore may represent patients with chemosensitive disease who were able to undergo an AHCT intervention. EMN02/HO95 was a randomized phase III trial that compared VMP as a consolidation treatment compared with

Full access

Shailender Bhatia and John A. Thompson

in Tables 1 and 2 , respectively. A thorough understanding of the resistance mechanisms to current therapies is critical for successful incorporation of novel therapies and combinations in the treatment algorithms. Besides the need to consolidate

Full access

David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Thomas Dilling, Michael Dobelbower, Ramaswamy Govindan, Mark Hennon, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Neelesh Sharma, Scott J. Swanson, James Stevenson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes

2015 ; 7 : 51 – 63 . 72. Zauderer MG Krug LM . Novel therapies in phase II and III trials for malignant pleural mesothelioma . J Natl Compr Canc Netw 2012 ; 10 : 42 – 47 . 73. Thomas A Hassan R . Immunotherapies for non

Full access

Elizabeth A. Nardi, Julie A. Wolfson, Steven T. Rosen, Robert B. Diasio, Stanton L. Gerson, Barbara A. Parker, Joseph C. Alvarnas, Harlan A. Levine, Yuman Fong, Dennis D. Weisenburger, C. Lyn Fitzgerald, Maggie Egan, Sharon Stranford, Robert W. Carlson, and Edward J. Benz Jr

centers are criticized for their higher costs of care; meanwhile, they develop novel therapies and diagnostics, train the next generation of health care providers, and often provide highly specialized and resource-intense services to patients that are not

Full access

Kelly G. Paulson and Shailender Bhatia

continuing the PD-1/PD-L1 pathway blockade, while adding other novel therapies on this backbone, to overcome immune evasion mechanisms. Cellular Immunotherapy: The presence of viral antigens provides an ideal target for cellular immunotherapies. Endogenous